Practical Considerations for Self-Administration of Subcutaneous Immunoglobulin G Utilizing Recombinant Human

Linda K Miars1, Michelle Tran, Kimberly Duff

  • 1Allergy Partners of North Texas Research, Dallas, Texas (Ms Miars); Division of Basic and Clinical Immunology, University of California, Irvine, Irvine, California (Dr Tran); and Baxalta US Inc, now part of Shire, Knoxville, Tennessee (Ms Duff). Linda K. Miars, LVN, is affiliated with Allergy Partners of North Texas Research in Dallas, Texas. Her interests in the field of infusion therapy include patient education and management of adverse reaction to immunoglobulin G (IgG) administered subcutaneously (IGSC) and IgG administered intravenously (IGIV). Michelle Tran, DNP, FNP-C, is affiliated with the University of California, Irvine in Irvine, California. Her interests in the field of infusion therapy include the management of IGIV adverse reactions and barriers to weight loss in patients with primary immunodeficiency diseases. Kimberly Duff, BSN, RN, has been a manager of clinical education in global medical affairs for Shire for the past 5 years. She has 31 years of experience in nursing, with the last 17 in the field of immunology. She provides clinical expertise to support the development of new products and helps others understand the patient experience. Ms Miars and Dr Tran have no conflicts of interest to report. Ms Duff is an employee of Shire. Editorial support was provided by BlueMomentum, a division of Ashfield Healthcare Communication (a UDG Healthcare plc company) and was funded by Shire.